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Abstract
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Pharmacotherapy includes a growing number of clinically effective medications for substance use
disorder, yet there are significant barriers to its adoption and implementation in routine clinical
practice. The Medication Research Partnership (MRP) was a successful effort to promote adoption
of pharmacotherapy for opioid and alcohol use disorders in nine substance abuse treatment centers
and a commercial health plan. This qualitative analysis of interviews (n = 39) conducted with
change leaders at baseline and at the end/beginning of 6-month change cycles explains how
treatment centers overcame obstacles to the adoption, implementation and sustainability of
pharmacotherapy. Results show that barriers to adopting, implementing and sustaining
pharmacotherapy can be overcome through incremental testing of organizational change strategies,
accompanied by expert coaching and a learning community of like-minded professionals. The
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greatest challenges lie in overcoming abstinence-only philosophies, establishing a business case
for pharmacotherapy, and working with payers and pharmaceutical representatives.

Keywords
Pharmacotherapy; medication-assisted treatment; substance use disorder; alcohol use disorder;
quality improvement

Introduction

Author Manuscript

A growing number of medications could transform addiction treatment similar to the effect
of selective serotonin reuptake inhibitors (SSRIs) on treatment for depression and anxiety
disorders. Buprenorphine, naltrexone, and extended-release naltrexone (XR-NTX,
Vivitrol®) are clinically effective when combined with evidence-based counseling and
patient education interventions.1 Studies, however, also catalogue the internal and external
barriers to adopting and implementing pharmacotherapy in routine clinical practice (e.g.,
staff resistance, insufficient program infrastructure, lack of knowledge about medications,
and complex ordering and reimbursement systems).2–5 This paper details not only the
internal and external barriers treatment centers in the Medication Research Partnership
(MRP) encountered in increasing use of pharmacotherapy, but also the strategies for
developing strong internal and external supports to overcome these barriers. The MRP, a
collaborative initiative which included a commercial health insurance company and
participating treatment centers, focused on improving access to medications for individuals
with opioid and alcohol use disorders.

Author Manuscript
Author Manuscript

An earlier initiative, Advancing Recovery forged quality-improvement partnerships between
state substance abuse agencies and treatment centers to address implementation barriers
associated with medication and psychosocial services. Twelve state/county agencies
responsible for alcohol and drug treatment led the implementation of evidence-based
treatments with participating addiction treatment centers. Most sites achieved a measurable
increase in the numbers of patients served with evidence-based practices, up from a baseline
of virtually no use.6 Advancing Recovery worked within the public sector where the payer
structure and the payer-provider relationship is typically less complex and more stable than
in commercial health plans.6 In the private sector, addiction treatment centers are typically
reimbursed by multiple health plans with an ever-changing structure of contracts,
formularies and payment rules. Bureaucratic churning and complexity characterize private
payment and reimbursement systems.2 Advancing Recovery used the Network for the
Improvement of Addictions Treatment (NIATx) model for process improvement to promote
the use of medication in publicly funded treatment centers.6–10 NIATx used simple strategies
to pilot rapid changes to improve the quality of addiction treatment.11 Participants created
“change teams” to rapidly test and monitor the effectiveness of small organizational changes
that promoted the use of adjunct pharmacotherapy. Once found effective, changes were
scaled up and adopted across the organization.7,8,12,13
The MRP tailored the NIATx and Advancing Recovery models to addiction treatment
centers contracting with a large commercial health plan and promoted adoption of
J Behav Health Serv Res. Author manuscript; available in PMC 2020 April 01.
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pharmacotherapy for alcohol and opioid use disorders in nine substance abuse treatment
centers in Delaware, Maryland, and Pennsylvania. Treatment programs who declined the
invitation to participate in the Partnership served as a non-intervention comparison group
and controlled for cyclical change in the industry. A quantitative analysis documented an
overall increase in the number of prescriptions filled for alcohol and opioid use disorders for
patients in MRP sites relative to the non-intervention comparison group.14 MRP clinics
experienced a 2.4-fold increase in patients with prescriptions for medication-management of
alcohol or opioid use disorders (13.2% at baseline to 31.7% at three years post MRP
initiation). MRP sites also increased the number of patients with prescriptions to treat opioid
use disorder from 17.0% (baseline) to 36.8% (three years post initiation), with smaller
changes observed in comparison sites (23.2% to 24.0%) and a three-year post initiation
adjusted difference-in-differences of 19% (95% C.I. = 8.5% – 29.5%, p = 0.000).
Medications for alcohol use disorders increased in both MRP (9.0% to 26.5%) and
comparison sites (11.4% to 23.1%).

Author Manuscript

Internal factors that contributed to increased medication use varied across sites. Overall,
internal changes implemented focused on improving clinical communication, training staff
on medications and how to talk with patients about medication options, changing workflow
to reduce patient wait time to first dose, educating patients and their families about
medications, and changing medical directors. External factors focused on strengthening
partnerships and improving patient handoffs back into the community. Communication with
pharmaceutical representatives, linkages to care, and payer expectations to use medications
provided the external environment necessary to support internal changes.2,14

Author Manuscript

This paper reports findings from a process evaluation that addressed how the gains were
achieved through the development of internal and external supports. Qualitative data over the
MRP’s duration were collected from all parties engaged in this effort to better understand
the barriers to and needed supports for adopting and implementing pharmacotherapy in
private sector addiction treatment.

Methods
The Medication Research Partnership

Author Manuscript

The MRP focused on improving access to medications for individuals in treatment for
opioid and alcohol use disorders. Each of nine treatment centers designated a “change
leader,” either an administrator or clinician to spearhead its effort, along with a two to five
member “change team” representing multiple sectors of the facility including admissions,
nursing, counseling, psychiatry, and management. Each center was assigned an expert coach
in implementation science who assisted change teams through monthly calls and a site visit.
Change leaders were coached to focus on one small change at a time, to track data on the
change, to communicate change data regularly to staff, and to include all levels of staff in the
change team and in communication about change progress or failure. The heart of change
team efforts was the Plan-Do-Study-Act (PDSA) rapid cycle testing of strategies to promote
use of medications.15, 16 Teams first developed and tested one change strategy confined to a
small portion of the organization. Through data monitoring and staff and patient feedback,
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change teams could determine effectiveness, allowing leadership to decide either to scale up
adoption, to modify, or to abandon the change strategy.17

Author Manuscript

The MRP included three six-month change cycles, and an 18-month sustainability phase to
lock in successful strategies organization-wide. Throughout, the MRP provided a wide range
of supports to the nine treatment centers in developing change strategies, overcoming
barriers to implementation, and building relationships outside of the organization to support
pharmacotherapy. Along with monthly coaching, “Learning sessions” brought all nine
change teams and the commercial health plan together to share successful and unsuccessful
promotion strategies. Learning sessions were held every seven months before/after each
change cycle, plus a final learning session near the end of the observation period. Additional
technical assistance was provided through periodic webinars, trainings, and other supports
from the health plan. Coaches also focused on making the business case for change through
understanding the process cost (e.g., staff time and materials) associated with medication
administration and the revenue impact associated with increased admissions and retention in
treatment.
Data collection

Author Manuscript

The MRP process evaluation used qualitative methods to track efforts in all nine treatment
centers and the health plan. Semi-structured interviews (n=39) conducted with change
leaders at baseline and within two months of the end of each six-month change cycle
captured decision-making around adapting, adopting, and abandoning each change strategy,
and plans for the next change cycle. Interviews conducted after completion of the MRP
addressed how changes were being sustained. Interview schedules maintained comparability
across sites and were conducted in a conversational manner to maximize opportunities for
change leaders to describe goals and experiences in their own words. Interviews were
digitally recorded and professionally transcribed. Other qualitative data sources included
field notes taken during coaching sessions (n=67), site visits (n=9), and learning sessions
(n=4).
Analysis

Author Manuscript

Qualitative analysis focused on the method of constant comparison to explore similarities
and differences across sites.18 Analysis and data collection were conducted on an on-going
basis to allow up-to-date adaptations to interview guides. Goals were to capture (1)
strategies for integrating pharmacotherapy into behavioral treatment, (2) internal and
external challenges and barriers to organizational change, and (3) preconditions for
sustaining change. Four research team members coded interview transcripts using the
qualitative software Atlas-ti 7.0. Research team members did not code interviews they had
conducted themselves to minimize any researcher biases or assumptions.
The research team developed a common coding scheme to facilitate cross-site analysis.
Codes were designed to flag material related to the study’s research questions as well as
themes independently introduced by interviewees. The coding structure remained flexible,
allowing the inclusion of new codes and analytic themes, and the dismissal of any that had
reached analytic saturation. Through iterations of coding, memo writing, and telephone
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meetings, the team developed hypotheses about key themes in the data and then returned to
the data looking for their confirmation, modification, or refutation.

Results
Treatment centers confronted three sequential phases in adopting, implementing, and
sustaining pharmacotherapy.19 At each stage, the MRP team adjusted its approach and tools
offered to help treatment centers overcome barriers to change. Timing varied across sites
depending on the magnitude of the barriers each faced and the effectiveness of change teams
and MRP coaches in overcoming them.
The decision to adopt pharmacotherapy

Author Manuscript

In deciding to adopt pharmacotherapies, change teams faced the perceived incompatibilities
between the use of medication and clinicians’ existing values and past experiences.
Treatment centers with strong medical leadership moved more quickly through this stage.
Almost uniformly, these clinicians largely held a “pro-medication” treatment philosophy—
usually those who had prior positive experiences prescribing medications for treatment, and
who championed the positive outcomes that medication, along with social-behavioral
treatment, could yield. This stage also went more smoothly in centers that approached the
MRP with supportive leadership and had the operational capacity to deliver medications.

Author Manuscript

When clinician attitudes were rooted in abstinence-only philosophies, and prior experience
with methadone and disulfiram, change was slower. Polarizing debates occurred between
change leaders and clinicians who assumed that being “pro-medication” necessitated being
“anti-behavioral therapy.” Some clinicians feared that adopting medications was tantamount
to dismissing behavioral therapy as ineffective. For these clinicians, methadone clinics
seemed to provide a cautionary tale:
[The doctor] would just say, take the medication. That’s all you need. Not go to 12
Step meetings, not go to church, not go see a therapist, not engage in some type of
positive program…And I think what they don’t want to do is create what we
already have, which is the stigma of methadone maintenance.
Change leaders also noted fears of repeating a “common” discourse with patients who asked
for medications:

Author Manuscript

[The client] doesn’t want to do [behavioral therapy]. And all he wants is
[buprenorphine]. And that’s just like, ‘just give me the antidepressant. Give me a
pill that will make it go away. And I don’t want to learn the behaviors to make the
changes I need to make.’
Some change leaders reported views that buprenorphine was the “new methadone,” fearing
diversion and the potential that their centers could become “drug mills:”
I think people saw [methadone] as a way for everybody to just function…I don’t
think [methadone or buprenorphine] work well when we give you the meds, and
then you go out on the street and you sell them, or you’re using anyway and still

J Behav Health Serv Res. Author manuscript; available in PMC 2020 April 01.
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getting high, because we’ve not changed your behavior and your attitude about
sobriety.
The MRP developed a toolkit of strategies to help move centers more quickly through the
decision to adopt. Central to this was formally educating clinicians about how medications
worked and that some forms of these medications were virtually immune to diversion. The
MRP’s learning sessions and webinars helped clinicians overcome these concerns so that
within six months, staff were no longer expressing concerns about diversion to the lead
team. Indeed, providers sometimes turned to moral arguments about withholding effective
forms of care. Concerns sometimes remained, however, about discharging medicated
patients into abstinence-only halfway houses.
Key to success in adoption was inclusiveness that allowed all center staff a voice. As one
change leader put it,

Author Manuscript

The first thing that had to happen with the [Quality Improvement] meetings was the
staff had to start to begin to believe that we just weren’t implementing stuff and that
they were part of the process.
Incrementalism was another key to success. When one center struggled to overcome
philosophical barriers to adding medication to recovery plans, change teams reported that
“half the staff was on board and half the staff wasn’t.” At this point, the center transitioned
to referring patients to outside providers while managing their doses in-house. Direct
experience with managing patients on medication increased so that after six months, the
center’s change leader could say:

Author Manuscript

The staff has definitely accepted [buprenorphine] as part of the culture here. It’s
part of who we are and what we are, and that it’s mentioned, it’s talked about…it’s
not a discussion that we have in staff. It’s just accepted they’re on [buprenorphine]
and we treat those clients much like if they have specific issues that are specific to
treatment, much like if there’s an opioid addict, that’s important to us, if they’re
male that’s important to us, if they’re female, if they’re a minority, if they’re on
[buprenorphine], then all those factors are part of that makeup…it’s part of who
they are and what they are.

Author Manuscript

Finally, a major theme throughout the MRP was uncertainty about the economic costs of
medications: “If the insurance doesn’t pay, ninety-five percent of the people or more are not
interested in obtaining medicated assisted treatment.” Even in centers with leadership who
believed that pharmacotherapy would be cost-effective, uncertainty remained about getting
accurate cost information, coverage by contracting health plans, and the mechanics of
reimbursement across multiple health plans, which was complex and difficult to predict:
It’s like a formulary. Well, there’s two things. Some insurance companies pay for
[XR-NTX]…under their medical benefit. Some pay it under the pharmacy benefit.
Some pay a little bit under medical and a little under pharmacy. So the setup of it is
a barrier at times because it’s so convoluted who’s paying for what and who you’re
supposed to talk to, you know, covered, etc.

J Behav Health Serv Res. Author manuscript; available in PMC 2020 April 01.
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The MRP responded by coaching change teams on how to make the “business case” for the
use of medication, focusing on reductions in costly readmissions and emergency room visits.
For some centers, this proved highly effective. In response to the business case, one change
leader concluded, “I feel—again just a forecast guess—that people will struggle to remain in
business if they don’t embrace [medications].”
From the decision to adopt to implementation

Author Manuscript

Once treatment centers had decided to offer pharmacotherapy, they faced many complexities
in providing this service in a clinically safe, cost-effective manner. Sites were new to the
complex ordering, reimbursement, and pre-authorization processes, particularly because
multiple payers with different formularies were involved; centers felt “at the mercy of the
insurance company.” Storage and mixing procedures were complex for some medications.
Residential programs struggled to find linkages to outpatient services where patients could
continue medications.
The MRP responded to these many barriers by breaking down the implementation process
into small, feasible steps. This was inherent in the Plan-Do-Study-Act (PDSA) cycle, which
encouraged sites to test single, manageable changes, and reframed expectations for the speed
and demands of change. As one center’s team leader described it:
Okay, now the real work begins…So it’s part of a development. And it will be
ongoing working documents where we develop it, and critique it, and change it, and
manipulate it so that the whole process is engaging. And then allowing the client
who’s not ready to say, okay, that’s fine. Right now you’re just getting your feet
wet. You’re waking up, and that’s fine. No sweat.

Author Manuscript

Coaches provided centers a menu of change options ranging from making patient referrals to
outside providers, to learning how to induct and maintain patients on medications. This
resulted in a wide variety of change projects across the nine treatment centers that ranged
from building referral networks, to streamlining intake processes, improving hand-offs,
formalizing protocols for determining eligibility, and monitoring physician prescribing. In
many cases, the simpler changes proved most impactful:
Just going to another building, another program across the street is scary. And
we’ve even talked about, why don’t you walk them over? So they can see where
they’re going, and what door to use and that…you know, it takes ten minutes out of
your day and it’s well worth our time.

Author Manuscript

Interviews with change leaders revealed that pharmaceutical representatives proved to be an
unanticipated external resource in overcoming barriers to implementation. One leader found
that pharmaceutical representatives could strengthen linkages to physicians in the
surrounding community to support discharged patients:
We worked very closely with our [pharmaceutical] rep. We really looked at getting
referrals for aftercare at facilities where there was actually a program not just a
[pill] mill…that we wanted people to get quality treatment afterwards. So we
worked with our [XR-NTX] rep, who worked with other [XR-NTX] reps in their
areas.

J Behav Health Serv Res. Author manuscript; available in PMC 2020 April 01.
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A change leader at a different center explained the benefits of pharmaceutical representatives
for clinician training:
As a result of the [change] project, people were able to delegate certain things, you
know, to me as the team leader, just to kind of keep it in focus, in addition to
working with the pharmaceutical company to provide ongoing training. So instead
of having a once a year visit with [the pharmaceutical representative], what I know
has happened over the past six months is [the pharmaceutical representative] has
been here at two or three times.
An additional outside resource was the commercial health plan participating in the MRP
which sent representatives to learning sessions, provided webinars about its pharmaceutical
coverage benefits, and system of medication preauthorization.

Author Manuscript

Throughout implementation, the MRP lead team emphasized the use of data and patient
feedback to evaluate the success of incremental changes, often providing the unexpected
benefits of making the case for the value of pharmacotherapies:
I really started to show [the change team and other staff] the opioid dropout rate
that we were having. And I would review the discharge for the entire facility and
show the differences, you know, break it down by counselor…I went over the
numbers for the discharge and showed them the stats…I think they were real
pleased with themselves, you know, the positive changes. I mean, it was dramatic. I
was very impressed.
Routinizing medication use for long-term sustainability

Author Manuscript

Once internal and external barriers to implementation had been overcome, treatment centers
faced the risks of reverting back to the old, familiar patterns, as well as the challenges of
adapting to changes in the environment that would demand modifications in procedures.
Conflicting philosophies, staff turn-over, inadequate staffing, poor adherence to medication
protocols, and the external environment—changes in payer and government policies—were
the key barriers observed at this stage.
The MRP approach gave treatment centers and their change teams control with strong
“ownership” of the MAT processes put in place. If further adaptations were needed over
time, centers were empowered and prepared to continuously adapt to future needs.
Designation of a “change leader” within the organization created an accountable person
responsible for the team’s success or failure:

Author Manuscript

I think once we started with the Partnership, I think it was pretty much we were
committed to getting this going. And we kind of used it as a vessel to keep us
motivated. The point to where like it actually had to fall under somebody’s
umbrella directly. You know what I mean? To me, that shows sustainability.
Routinization called for weaving medication protocols into the fabric of day-to-day clinical
care. Centers made clinicians accountable for directly referring patients to pharmacotherapy
without spending critical time on obtaining approval by supervisors and directors. By
increasing treatment continuity, patients were less likely to withdraw from care or fail to
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show at follow-up appointments. For some, devolving decision-making on use of medication
to clinicians and patients had the unexpected benefit of improving the provider and patient
experience:
I think with accountability comes sustainability. The staff loves it. The patient
feedback is phenomenal. The simplicity of how to get somebody in makes it like
easy for the clinicians just to make direct referrals. Like in the pilot program, they
would have to tell me who the patient was. Now they can just make direct referrals.

Discussion

Author Manuscript

The MRP sought to accelerate the adoption of pharmacotherapy for alcohol and opioid use
disorders in private-sector substance abuse treatment. It brought together a group of
treatment centers and external partners operating in the same market as a “learning
community” to collaboratively problem-solve around barriers to the use of medication.
Through incrementalism, using Plan-Do-Study-Act cycles, and coaching, change teams
within treatment centers developed internal and external supports needed to sustain MAT
over time. Most importantly, patients in comparison programs that did not participate in the
Partnership were less likely to receive medications to support recovery from alcohol and
drug use disorders at the end of the three-year observation period.

Author Manuscript

Credible evidence that MAT was beneficial to their clients fueled strong internal support
among some treatment centers and underlined the importance of making data-driven
decisions and using data to inform change team members about the impact of the
intervention.6,20,21 Development and use of measurement and feedback systems are integral
components of organizational change. During implementation, these systems aggregated and
reported clinical data over time.22–24 Regular staff updates about data feedback from
medication implementation can motivate staff to sustain their efforts because it
communicates consistent messaging about the benefits of medication for clients and
families.25–28 Further, data reports may allow staff to make internal and external
comparisons. Data-driven organizations using feedback reports and communicating
outcomes to staff are more likely to be successful in their efforts to improve.20 The findings
support the use of audit and feedback reports to drive behavioral and organizational change.
29–31

Author Manuscript

While internal supports were strong among treatment centers, efforts to implement and
sustain the use of medication to support recovery must also address external barriers.
External supports proved key to successful changes within treatment centers, a finding
consistent with frameworks that suggest internal and external attributes influence the
implementation and sustainability of organizational change.32,33 This included commercial
health care payers willing to streamline and train providers on reimbursement procedures,
treatment centers seeking support from pharmaceutical representatives willing to train
clinicians and promote referral networks, and community-based primary care physicians
willing to serve as referral destinations for patients maintained on pharmacotherapy
following care. When implementing organizational change, the providers’ strategic plan
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must address and understand how external partners and regulatory changes influence
success.34,35
The MRP prepared centers for success by designating accountable change leaders,
routinizing medication protocols throughout clinical care regimes, and providing the
framework to strengthen external supports. This alignment of supports inside treatment
centers with supports outside their walls was an essential task of sustaining medication use.
36

Author Manuscript

A fundamental challenge with adopting any innovation is increased organizational
uncertainty.19 The MRP reduced uncertainty by introducing small changes on a limited pilot
basis in ways that reduced the strains on staff time and organizational resources, while
increasing external supports, resulting in lowered perceived risk of making
pharmacotherapies available to patients. The findings suggest that strategies for overcoming
barriers to use of medication are likely to be most successful when they break down stages
of adoption and implementation into smaller, manageable pieces, curate strong internal
support through data reporting and sharing, and develop external support from health care
plans and through linkages with pharmaceutical companies and community-based
physicians. This allows treatment centers to overcome internal and external challenges
through less risky trial and error, gradually building confidence in their efforts,
experimenting with needed adjustments, all with the attitude that organizational change is
more of a process than an event.

Author Manuscript

Patient access to medications to support recovery is improving. Data from the National
Survey of Substance Abuse Treatment Services document increases in the number of
programs making pharmacotherapy available to patients and increases in the number of
patients using medication.37 Programs, counselors, and patients apparently see more stable
recoveries and less craving. Generally, however, the percent of patients who receive
medication remains limited.38
Limitations

Author Manuscript

Study sites were limited in number with their geographic concentration in Maryland,
Delaware, and Pennsylvania. Moreover, the study was confined to building partnerships with
one major commercial health plan even though addiction treatment centers engage with
multiple plans. Interviews were limited to change leaders; other staff may have had different
perceptions of barriers and facilitators. The claims data used in the analysis did not include
direct measures of patient outcomes. It is unknown if patient outcomes improved. Analysis
of data on hospitalizations during the study period were inclusive because of large statistical
variation in the data.
Some of the treatment programs developed relationships with pharmaceutical representatives
from Alkermes (manufacturer of extended-release naltrexone). The representatives provided
staff training on the medication and the ordering and administration of the medication and
helped with linking patients to community prescribers for subsequent injections. Programs
valued this assistance because the medication was new to them and there are complexities in
ordering and administration of the medication2. The evaluation noted which treatment
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programs reported using the services to facilitate use of the medication and noted the
reported benefits. The services are a resource available to any community-based addiction
treatment service and were not provided as part of the MRP. Programs that do not develop
relationships with pharmaceutical representatives may be less likely to initiate use of new
medications.

Implications for Behavioral Health

Author Manuscript

The MRP helped substance abuse treatment centers accelerate adoption and implementation
of evidence-based medications for recovery. Along the way, centers developed new
capacities for strategically realigning themselves with a private-sector health care
environment in which they will be playing an increasingly integrated role. With health
reform, substance abuse treatment is becoming more integrated with medical care, thus
laying fertile ground for the diffusion of pharmacotherapy to promote recovery. Strategies
such as the MRP that support treatment centers in this integration process may benefit from
the stability of private-sector treatment systems while providing patients with new options
for recovery.
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